Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the safety and efficacy of RDX5791 for constipation-predominant irritable bowel syndrome has completed and results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Constipation-predominant Irritable Bowel Syndrome

Drugs mentioned

• RDX5791

Snippet

Sponsor: Ardelyx | Conditions: Constipation Predominant Irritable Bowel Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2019-10-15